Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Shares Outstanding (Weighted Average) (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $8.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 1.52% year-over-year to $8.6 million, compared with a TTM value of $8.6 million through Sep 2025, up 1.52%, and an annual FY2024 reading of $8.5 million, up 2.48% over the prior year.
  • Shares Outstanding (Weighted Average) was $8.6 million for Q3 2025 at Sanara MedTech, up from $8.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $8.6 million in Q3 2025 and bottomed at $6.8 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $8.1 million, with a median of $8.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 43.45% in 2021, then grew 1.45% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $7.3 million in 2021, then grew by 7.7% to $7.9 million in 2022, then rose by 4.71% to $8.3 million in 2023, then grew by 2.48% to $8.5 million in 2024, then grew by 1.91% to $8.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SMTI at $8.6 million in Q3 2025, $8.6 million in Q2 2025, and $8.6 million in Q1 2025.